Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Funding Agency
Foreign For Profit
(Foreign-FP)
Recent Grants
A Phase I/II, Randomized, Double-blind, Sham Control Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gen
Active
·
2024
·
$1.1M
Personalized Approaches to Evaluating the Impacts of Pets on Human Mental Health and Wellbeing in Geographically Diverse and Older Adult Populations
Active
·
2024
·
$552.8K
Komatsu Smart Control Jumbo Underground Proving
Active
·
2024
·
$495.6K
SOS-AMI Multi-Center, Double-Blind, Randomized , Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Self-Administered Subcutaneous Selatogrel for Prevention of All-Cause D
Active
·
2024
·
$447.6K
A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizu
Active
·
2024
·
$444.3K
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
Active
·
2024
·
$440.6K
TSMC & EPO Student Immersion Membership Agreement
Active
·
2024
·
$345.5K
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomonas aeru
Active
·
2024
·
$306.4K
A Multi-Center, Phase IIA, Randomized, Double-Blind, Prospective, Active Placebo- Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa- Induced Dyskinesia in Subjects
Active
·
2024
·
$303.6K
An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Active
·
2024
·
$275K
79.7M Funding
196 People
229 Grants
People
Buell Jannuzi
Astronomy
Department Head
Jeffrey Kingsley
Steward Observatory
Associate Director
Donata Vercelli
Cellular & Molecular Medicine
Professor
Oksana Pivniouk
Asthma/Airway Disease Rsch Ctr
Research Laboratory Manager I
Ashley Michael
Asthma/Airway Disease Rsch Ctr
Research Technologist II
Avery DeVries
Asthma/Airway Disease Rsch Ctr
Researcher/Scientist III
Dayna Anderson
Asthma/Airway Disease Rsch Ctr
Research Technologist II
Vadim Pivniouk
College of Medicine - Tucson
Associate Research Professor
Darren Cusanovich
Cellular & Molecular Medicine
Assistant Professor
Sunil Banskar
Asthma/Airway Disease Rsch Ctr
Researcher/Scientist III
